Europe Plasma Protein Therapeutics Market

Europe Plasma Protein Therapeutics Market Size (2024 to 2029)

The plasma protein therapeutics market size in Europe was estimated at USD 9532.66 Million in 2024. It is expected to reach USD 14526.43 Million by 2029, growing at a staggering CAGR of 7.99% between 2024 to 2029.

In the recent past, plasma protein became prominent in medical science. There are also many technological advancements in this sector. The primary process of the plasma protein is, fractionating the protein from plasma. This process is also the most economical and less costly process, which is one of the significant factors promoting the growth rate of the European plasma protein therapeutics market.

This market is also introducing new therapies such as new plasma-derived therapies. These therapies are gaining the demand for the European plasma protein therapeutics market. In addition, the prevalence of various diseases has noticed growing in the recent past. Therefore, the increasing prevalence of diseases such as Rabies, Tetanus, Hepatitis A&B, and varicella is expected to favor the market's growth rate.

Many new opportunities are being introduced in this market to accelerate the market growth. Increasing treatment of the diseases and recent technological advancements in this market from the research department is improving the efficiency of the plasma proteins. These technological advancements are boosting the market. By knowing about its efficiency, plasma proteins are starting to be used around the world. Therefore, people are interested in detecting the disease in the starting period. 

However, strict government policies, high cost of manufacturing, and complex treatment and manufacturing are a few of the factors expected to hamper the market's growth rate.

This research report on the European plasma protein therapeutics market has been segmented and sub-segmented into the following categories

Europe Plasma Protein Therapeutics Market Analysis By Type

• Immunoglobulins

• Albumin

• Coagulation Factor

• Alpha-1 Proteinase Inhibitor

• Others

Europe Plasma Protein Therapeutics Market Analysis By Application

• Hemophilia

• Primary Immunodeficiency Disorder

• Idiopathic Thrombocytopenic Purpura

• Secondary Immunodeficiency

• Others

Europe Plasma Protein Therapeutics Market Analysis By Country

• UK

• France

• Spain

• Germany

• Italy

• Russia

• Sweden

• Denmark

• Switzerland

• Netherlands

• Turkey

• Czech Republic

• Rest of Europe

Germany is predicted to account for the largest share of the European plasma protein therapeutics market during the forecast period. Many disorders such as bleeding disorders, autoimmune disorders, neurological and immune deficiency disorders are increasing. The rise in the population is also affecting the market's growth as neurological disorders are common in the elderly population.

Followed by Germany, the United Kingdom is predicted to occupy the second-largest share in the European market during the forecast period. Many key players in the biotechnology and pharmaceutical sectors are increasing their investments in the research and development department, increasing the market's growth. The research and development department is expanding the applications of plasma proteins is boosting the market. Around the world, the usage of therapeutic protein drugs is increasing in the treatment of clinical symptoms. It is introducing new opportunities in this market and is expected to drive this market.

KEY MARKET PLAYERS

Major market participants in the European Plasma Protein Therapeutics Market are Grifols, CSL Behring, Baxter, Krdrion, China Biologics, Octapharma, and Chengdu Inst Shire Plc.